Concerto HealthAI announced today the company entered a precision oncology collaboration with Pfizer using Concerto HealthAI’s eurekaHealth platform, artificial intelligence (AI) models and data from Electronic Medical Records (EMR) and healthcare claims. Data from clinical practices participating in the American Society of Clinical Oncology’s CancerLinQ initiative—which represents one of the most comprehensive real-world data sets—and other practices throughout the U.S. will be used for the collaboration. The collaboration’s goal is to quicken the pace for actionable patient insights for Pfizer‘s investigational therapies and commercialized therapeutics used in the treatment of solid tumors and hematologic malignancies.
“Pfizer believes real-world data have tremendous potential to inform how we develop and use medicines to improve patient outcomes,” said Chris Boshoff, M.D., Ph.D., chief development officer, Oncology, Pfizer Global Product Development. “We are pleased to work with Concerto HealthAI to accelerate insights and outcomes studies that may lead to a more comprehensive understanding of patients’ experience with our medicines.”
“This collaboration aims to find and help patients who may benefit from new therapeutic combinations,” said Jeff Elton, Ph.D., CEO of Concerto HealthAI. “We are using our definitive real-world data, AI-enabled abstraction, data science expertise, and strength in outcomes research to identify new and more precise treatment options; refine study designs; and speed up the completion times for various outcomes studies.”
A Concerto HealthAI-Pfizer joint steering committee will oversee the collaboration. The first outcomes research and publications are expected in early 2020.